WALNUT CREEK, California, USA & SUZHOU, China | June 3, 2026
Dark Horse Consulting Group (DHCG) and Altruist Biologics have signed a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development, manufacturing, and global commercialization of biologic therapies. The partnership combines DHCG’s expertise in regulatory strategy, CMC development, clinical operations, quality compliance, supply chain management, and commercial launch planning with Altruist Biologics’ large-scale cGMP manufacturing infrastructure in China. Together, the organizations intend to provide biotechnology and pharmaceutical companies with a streamlined pathway for advancing biologic products from development through commercial manufacturing. The collaboration arrives at a time when China continues to strengthen its position as a global hub for biologics manufacturing, offering advanced infrastructure, competitive production costs, and an increasingly mature regulatory environment for innovative therapies.
Strategic Collaboration Bridges Development and Manufacturing
The newly established partnership is designed to help sponsors navigate one of the most complex challenges in biologics development: aligning manufacturing execution with evolving global regulatory requirements. Through the collaboration, clients will gain access to integrated services spanning cell line development, process optimization, analytical method development, formulation development, drug substance manufacturing, drug product manufacturing, and antibody-drug conjugate (ADC) production.
DHCG will provide strategic guidance across regulatory, quality, nonclinical, and clinical development functions, while Altruist will contribute extensive manufacturing capabilities through its state-of-the-art facilities in Suzhou and Hangzhou. By combining consulting expertise with end-to-end manufacturing services, the companies aim to reduce development risk, improve operational efficiency, and accelerate the transition from research-stage programs to clinical and commercial production.
China Emerges as Global Biologics Manufacturing Hub
Advertisement
The partnership reflects growing international interest in leveraging China’s rapidly expanding biologics manufacturing ecosystem. Over the past decade, China has invested heavily in advanced biopharmaceutical infrastructure, creating a highly competitive environment for large-scale biologics production. Altruist Biologics operates advanced cGMP-certified manufacturing facilities with a total production capacity of 232,000 liters, including four 20,000-liter bioreactors at its Hangzhou site. These facilities support a broad range of biologic modalities, including monoclonal antibodies, bispecific antibodies, fusion proteins, and antibody-drug conjugates.
However, many international companies continue to face challenges when navigating China’s regulatory requirements, quality standards, and Chemistry, Manufacturing, and Controls (CMC) expectations. The DHCG-Altruist collaboration is specifically structured to address these challenges by providing sponsors with coordinated expertise capable of bridging regional regulatory and manufacturing differences while supporting global commercialization objectives.
Supporting Faster Access to Biologic Innovation
Executives from both organizations emphasized that the agreement is intended to create a more efficient pathway for companies seeking to access China’s manufacturing capabilities while maintaining compliance with international regulatory standards. The combined offering is expected to benefit emerging biotechnology companies as well as established pharmaceutical organizations developing next-generation biologic therapies. Areas of focus include monoclonal antibodies, bispecific therapies, antibody-drug conjugates, and other advanced biologic modalities that require sophisticated manufacturing processes and rigorous quality oversight.
As global demand for biologics continues to rise, strategic collaborations that integrate development expertise with manufacturing infrastructure are becoming increasingly important for accelerating innovation and reducing time-to-market. The new alliance positions DHCG and Altruist Biologics to support developers throughout the product lifecycle, from early-stage planning through commercial-scale production. By simplifying access to world-class manufacturing resources and regulatory expertise, the partnership has the potential to strengthen global biologics development while helping bring critical therapies to patients more efficiently across international markets.
Source: Dark Horse Consulting Group press release
